Insights

  • Date

  • Content Type

  • Reset

Article

Managing complex GMO requirements for gene therapy clinical trials

23.08.22

By Liron Sarid-Krebs

Regulators and industry organizations have raised concerns that Europe may be falling behind the United
Read More

Article

Europe’s complex reimbursement process puts access to ATMPs at risk

25.07.22

By By Emma Cheesman-Ungstrup and Alberto Rubio

A potential crisis with advanced therapy medicinal products (ATMPs) is looming in Europe. Concerns over
Read More

Article

Run like clockwork | Building successful partnerships with scientific due diligence

1.07.22

By Diane Seimetz & Joerg Schneider

For biotech companies and academic developers wishing to partner with larger firms is perhaps best…
Read More

Article

Bridging the perceived regulatory guideline gap for innovative medicines

21.06.22

By Jörg Schneider

There is a perception that regulatory guideline gaps across advanced therapeutic medicinal products (ATMPs) –
Read More

Article

PRIME versus ILAP: Selecting the right pathway for gene therapy innovators

21.06.22

By Francesco Lanucara

To all intents and purposes, EMA’s PRIME and MHRA’s Innovative Licensing and Access Pathway (ILAP)
Read More

Article

Scientific Due Diligence: The Key to Successful Partnerships

16.06.22

By Diane Seimetz & Jörg Schneider

Planning for partnering, mergers and acquisitions must be done carefully, particularly if you need to
Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more